Open Access

Bacteroides fragilis metabolises exopolysaccharides produced by bifidobacteria

  • David Rios-Covian1Email author,
  • Isabel Cuesta2,
  • Jorge R. Alvarez-Buylla2,
  • Patricia Ruas-Madiedo1,
  • Miguel Gueimonde1 and
  • Clara G. de los Reyes-Gavilán1
BMC MicrobiologyBMC series – open, inclusive and trusted201616:150

https://doi.org/10.1186/s12866-016-0773-9

Received: 27 January 2016

Accepted: 12 July 2016

Published: 15 July 2016

Abstract

Background

Bacteroides fragilis is the most frequent species at the human intestinal mucosal surface, it contributes to the maturation of the immune system although is also considered as an opportunistic pathogen. Some Bifidobacterium strains produce exopolysaccharides (EPS), complex carbohydrate polymers that promote changes in the metabolism of B. fragilis when this microorganism grows in their presence. To demonstrate that B. fragilis can use EPS from bifidobacteria as fermentable substrates, purified EPS fractions from two strains, Bifidobacterium longum E44 and Bifidobacterium animalis subsp. lactis R1, were added as the sole carbon source in cultures of B. fragilis DSMZ 2151 in a minimal medium. Bacterial counts were determined during incubation and the evolution of organic acids, short chain fatty acids (SCFA) and evolution of EPS fractions was analysed by chromatography.

Results

Growth of B. fragilis at early stages of incubation was slower in EPS than with glucose, microbial levels remaining higher in EPS at prolonged incubation times. A shift in metabolite production by B. fragilis occurred from early to late stages of growth, leading to the increase in the production of propionate and acetate whereas decrease lactate formation. The amount of the two peaks with different molar mass of the EPS E44 clearly decreased along incubation whereas a consumption of the polymer R1 was not so evident.

Conclusions

This report demonstrates that B. fragilis can consume some EPS from bifidobacteria, with a concomitant release of SCFA and organic acids, suggesting a role for these biopolymers in bacteria-bacteria cross-talk within the intestine.

Keywords

Bacteroides fragilis Exopolysaccharides Bifidobacterium MALLS Heteropolysaccharides

Background

The colonic microbiota is a complex community whose metabolic activity influences our health and nutritional status through diverse pathways [1]. Microbiota of adult healthy people is dominated by the phyla Firmicutes and Bacteroidetes, even though the composition at the species level is highly variable among individuals [2, 3]. Members of this microbiota are able to degrade complex polysaccharides and, therefore, genes involved in the degradation and consumption of these compounds are widespread among the genomes of microbiota-resident species [4, 5]. In this respect, the genus Bacteroides has the ability to use a wide range of carbohydrates, this ability varying as depending on the species considered [6]. Bacteroides is an anaerobic, bile-resistant, non-spore forming, and Gram negative rod [7] that accounts for up to 20–50 % of the total microbiota in most individuals [8]. Bacteroides fragilis is the most frequent species at the mucosal surface [9] and can contribute to the development and maturation of the host immune system [10]. This species has an extraordinarily good adaptability to environmental changes due to its capacity to regulate the cell surface [11]. Consequently B. fragilis is the clinical isolate most frequently found in systemic infections, this microorganism being then considered as an opportunistic pathogen [7].

Exopolysaccharides (EPS) are complex carbohydrates located outside the cell; some Bifidobacterium strains, as well as many other microorganisms, are able to produce these polymers [12]. The synthesis of these compounds in the intestine has not been demonstrated yet. However, it has been proven in vitro that the presence of bile, which is released to the small intestine during digestion, stimulates the production of EPS by bifidobacteria [13]. EPS could be constituted either by a unique type of monomer, named as homopolysaccharides (HoPS), or by more than one monosaccharide type, then known as heteropolysaccharides (HePS). All bifidobacterial EPS characterized until present are HePS [14].

Differential growth of members from the genus Bacteroides in the presence of EPS isolated from Lactobacillus and Bifidobacterium strains has been previously reported [15, 16]. Particularly, two EPS fractions isolated from Bifidobacterium longum E44 and Bifidobacterium animalis subsp. lactis R1, have shown the capacity to act as fermentable substrates by the intestinal microbiota, thus promoting the increase of Bacteroides populations in faecal cultures [15, 17]. Specific changes have been demonstrated as well in the metabolism of B. fragilis when grown in an undefined and complex medium in the presence of EPS E44 and R1 as compared with cultures in glucose [18]. Although these studies suggest that Bacteroides can use bifidobacterial EPS as fermentable substrates, this had not yet been effectively proven. In the present work, we assessed this question by testing the ability of B. fragilis DSMZ 2151 to growth in a minimal medium at the expenses of EPS from bifidobacteria when they are the sole carbon and energy source available.

Methods

Bacterial strains and culture media

Frozen stocks of B. fragilis DSMZ 2151 (DSMZ bacterial pure collection, Braunschewig, Germany) were reactivated in Gifu anaerobic medium (GAM) broth (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 0.25 % (w/v) L-cysteine (Sigma Chemical co., St. Louis, MO, USA) (named GAMc) and incubated overnight at 37 °C in an anaerobic cabinet (Mac 100; Don Whitley Scientific, West Yorkshire, UK) under a 10 % H2, 10 % CO2, and 80 % N2 atmosphere. pH free batch cultures of B. fragilis were performed in a modified minimal medium (MM) previously used in B. fragilis metabolism studies [19]. Briefly, the medium contained per litre: (NH4)2SO4, 1 g; KH2PO4, 0.9 g; NaCl, 0.9 g; CaCl2 · 2H20, 26.5 mg; MgCl · 6H20, 20 mg; MnCl2 · 4H20, 10 mg; FeSO4 · 7H20, 4 mg; CoCl2 · 6H20, 1 mg; resazurin, 1 mg; vitamin B12, 10 μg; vitamin K1, 2 mg; and haemin, 4 mg. MM was supplemented with 0.5 % (w/v) of glucose, EPS E44 or EPS R1 and the final pH of the medium ranged between 7.6 and 7.9. MM was inoculated with a 1 % (v/v) overnight culture of B. fragilis in GAMc in a final volume of 10 mL. A culture of B. fragilis inoculated in MM without carbon source added was used as a negative control. Potential changes over time in the characteristics of the EPS fractions during incubation not due to the microbial action were monitored in uninoculated MM added with EPS. Bacterial growth was monitored by counting in agar-GAMc plates at 0, 24, 48, 72 and 144 h of incubation. Experiments were run in triplicate using the same inoculum in all conditions.

EPS isolation

The EPS fractions were obtained from the strains B. animalis subsp. lactis IPLA R1 [20], a dairy origin strain, and B. longum IPLA E44 [21], a faecal isolate from a healthy adult faeces. Cellular biomass was harvested with ultrapure water from agar-MRS (Biokar, Allone, France) plates with 0.25 % (w/v) L-cysteine (Sigma) and incubated for 3 days at 37 °C under anaerobic conditions [22]. In brief, EPS was separated from the cellular biomass by gently stirring overnight with one volume of 2 M NaOH at room temperature. Then, cells were removed by centrifugation and EPS were precipitated from the supernatant with two volumes of absolute cold ethanol for 48 h at 4̊ C. After centrifugation at 10,000 x g for 30 min at 4̊ C, the EPS fraction was resuspended in ultrapure water and dialyzed against water during 3 days in 12- to 14-kDa molecular weight cut off dialysis tubes (Sigma). The protein content of the polymers was determined by the BCA protein assay kit (Pierce, Rockford, IL, USA) following the manufacturer’s instructions. Finally, EPS fractions were freeze-dried. The EPS E44 and R1 fractions contained 2.25 % and 1.99 % protein, respectively.

To check the purity of the EPS and test for the eventual presence of bacterial glycogen, EPS E44 and R1 fractions and glycogen (Roche, Switzerland) were digested with α-amylase (Sigma, USA) and/or pullulanase (Sigma, USA) and degradation profiles were compared. Digested samples were run in a TLC gel as described by Koropatkin and Smith [23]. In brief, each reaction mixture contained 1 mg/mL of substrate (EPS R1, EPS E44 or commercial glycogen) and 22 μg/mL of one or both enzymes in a 20 mM HEPES buffer. After 4 h of digestion at 37 °C, 6 μl of each sample reaction were placed and dried in a TLC Silica Gel 60 (Merk, Germany). Gels were transferred to a solvent chamber with a 3:1:1 mixture of isopropanol: ethylacetate: water, run for 3 h and revealed by irrigating a 5 % sulfuric dilution in ethanol and were dried at 120 C° for 10 min. (Additional file 1: Figure S1).

Metabolite analysis and EPS molar mass distribution and quantification

Organic acids (lactic, succinic and formic) formed during incubation were analysed by HPLC. Cell-free supernatants from cultures were filtered (0.2 μm) and quantified using an Alliance 2695 module injector, a PDA 966 photodiode array detector, a 2414 differential refractometer detector and the Empower software (Walters, Mildford, MA), following the chromatographic conditions described previously [22]. The weight average molar mass (Mw) distribution of EPS fractions was determined in the same equipment by size-exclusion chromatography (SEC) using two different columns placed in series, TSK-Gel G3000 PWxL and TSK-Gel G5000 PWxL (Supelco-Sigma) and the multiangle laser light scattering (MALLS) detector DawnHeleos II (Wyatt Europe GmbM, Dembach, Germany) as described previously [22]. The EPS peaks were detected and quantified with the refractive index detector, using standards of dextran (Fluka-Sigma) of different molar masses; the presence of proteins was monitored through a PDA detector set at 220 nm [17]. Short chain fatty acids (SCFA; acetic and propionic) were quantified in the supernatants by Gas Chromatography (GC) using a system composed of a 6890 N gas chromatograph (Agilent Technologies Inc., Palo Alto, CA, USA) connected with a FID detector (Agilent) and a mass spectrometry (MS) 5973 N detector (Agilent) as described previously [15]. Concentrations were expressed in millimolar (mM).

Statistical analysis

One way ANOVA statistical tests was run to compare the evolution of the different parameters analysed along time or among cultures with the different carbon and energy sources by means of the IBM SPSS software, version 22.00 (IBM, Armonk, New York, USA). SNK post-hoc test was used when required.

Results

The digestion pattern of EPS fractions E44 and R1 with the enzymes α-amylase (endohydrolysis of 1,4- α-D-glucosidic linkages) and pullulanase (endohydrolysis of 1,6-α-D-glucosidic linkages), were clearly different from that of glycogen (Additional file 1: Figure S1). This indicates that the release of intracellular glycogen during the process of obtaining the EPS fractions is negligible. Therefore, the results obtained through our work should be related with EPS polymers.

The metabolite production and growth pattern of B. fragilis DSMZ 2151 was dependent on the carbon source present in the culture medium. The final pH attained with glucose (6.52 ± 0.16) was significantly lower than with EPS E44, EPS R1, and without carbon source (p < 0.05) (7.62 ± 0.02, 7.66 ± 0.01 and 7.73 ± 0.05 respectively). The pH values remained unchanged in MM without carbon source added whereas bacterial counts increased 1.3 log units from time 0 (7.02 ± 0.08 log ufc mL−1) to 24 h of incubation in such conditions, probably due to the metabolic inertia of the inoculum (Table 1). At 24 h of incubation microbial counts reached were 1.22 log ufc mL−1 higher in glucose and 0.6–0.8 greater in EPS than in the control MM medium without any carbon source added (p < 0.05) (Table 1). From that point on, the time course of B. fragilis growth was different depending on the carbon source, and microbial population levels remained generally higher in EPS than in glucose at late stages of growth (from 48 h of incubation) (Table 1). Thus, microbial counts in glucose continuously decreased from 24 h to the end of incubation (p < 0.05). In contrast, levels of B. fragilis with both EPS remained largely unchanged from 24 to 72 h. From that time population levels decreased with both polymers, this decrease being much more pronounced with EPS R1 than with EPS E44.
Table 1

Growth and metabolic parameters of B. fragilis grown in glucose, EPS or without carbon source

Carbon source

Time (h)

Acetic acid

Propionic acid

Lactic acid

Succinic acid

Formic acid

Total metabolites*

Acetic/Propionic

Propionic/Succinic

Acetic/Lactic

Bacterial counts+

Glucose

24

13.00 ± 0.41D

4.35 ± 0.63C

14.81 ± 0.27B

3.46 ± 0.19a B

7.33 ± 0.15D

42.95 ± 1.40a C

3.02 ± 0.35C

1.25 ± 0.12A

0.88 ± 0.01A

9.58 ± 0.07d C

 

48

13.28 ± 0.74C

4.69 ± 0.21C

17.11 ± 1.26B

3.75 ± 0.27a B

6.86 ± 0.38D

45.73 ± 1.22ab D

2.83 ± 0.08D

1.25 ± 0.13A

0.78 ± 0.07A

8.47 ± 0.16c B

 

72

13.80 ± 0.53C

5.04 ± 0.47D

16.15 ± 1.01B

4.37 ± 0.18b C

7.59 ± 0.12C

47.11 ± 0.41b C

2.75 ± 0.18D

1.15 ± 0.09A

0.86 ± 0.09

7.76 ± 0.06b A

 

144

13.66 ± 0.26D

4.96 ± 0.32D

15.27 ± 0.87B

4.56 ± 0.52b B

7.26 ± 0.45C

46.02 ± 1.96ab D

2.76 ± 0.15C

1.09 ± 0.06A

0.90 ± 0.05A

7.46 ± 0.17a B

EPS E44

24

1.24 ± 0.06b B

0.78 ± 0.08b A,B

0.45 ± 0.07b A

0.12 ± 0.02A

0.43 ± 0.04a B

3.01 ± 0.11a B

1.60 ± 0.10a B

6.78 ± 0.27D

2.83 ± 0.53a A

9.17 ± 0.12c B

 

48

0.93 ± 0.08a A,B

0.39 ± 0.08a A

0.95 ± 0.05c A

-

1.27 ± 0.24b C

3.56 ± 0.22b C

2.44 ± 0.30b C

ND

0.98 ± 0.12a A

8.91 ± 0.02b C

 

72

1.89 ± 0.10c B

0.95 ± 0.13b B

0.77 ± 0.08c A

-

1.67 ± 0.46b B

5.31 ± 0.34c B

2.01 ± 0.19ab C

ND

2.48 ± 0.38a

9.05 ± 0.05bc B

 

144

5.53 ± 0.08d C

2.75 ± 0.13c C

0.26 ± 0.15a A

0.13 ± 0.05A

1.40 ± 0.31b B

10.07 ± 0.39d C

2.01 ± 0.12ab B

25.22 ± 11.55B

26.24 ± 12.29b A

8.68 ± 0.14a C

EPS R1

24

1.70 ± 0.11a C

1.37 ± 0.12b B

0.16 ± 0.10b A

0.26 ± 0.05b A

0.73 ± 0.25a C

4.22 ± 0.09a B

1.25 ± 0.03a B

5.40 ± 0.54b C

14.03 ± 7.32a B

9.01 ± 0.09b B

 

48

1.40 ± 0.22a B

0.82 ± 0.12a B

0.49 ± 0.09c A

0.15 ± 0.01a A

1.92 ± 0.12c B

4.81 ± 0.37b B

1.70 ± 0.08b B

5.64 ± 0.55b B

2.86 ± 0.12a B

9.17 ± 0.09b D

 

72

2.08 ± 0.10b B

1.44 ± 0.16b C

0.12 ± 0.09b A

0.26 ± 0.00b B

1.35 ± 0.18b B

5.25 ± 0.09b B

1.45 ± 0.11a B

5.62 ± 0.62b B

25.26 ± 19.65a

9.15 ± 0.13b B

 

144

3.13 ± 0.18c B

1.70 ± 0.09c B

0.02 ± 0.01a A

0.53 ± 0.02c A

1.27 ± 0.26b B

6.65 ± 0.34c B

1.85 ± 0.20b B

3.21 ± 0.29a A

>100b B

6.73 ± 0.21a A

WCS

24

0.21 ± 0.05a A

0.26 ± 0.03a A

-

0.11 ± 0.07a A

0.09 ± 0.03a A

0.72 ± 0.12a A

0.79 ± 0.12A

2.33 ± 0.43 B

ND

8.36 ± 0.15c A

 

48

0.27 ± 0.05a A

0.34 ± 0.03b A

-

0.21 ± 0.01b A

0.17 ± 0.03b A

1.01 ± 0.05a A

0.79 ± 0.10A

1.66 ± 0.21A

ND

8.10 ± 0.06c A

 

72

0.35 ± 0.06a A

0.36 ± 0.00b A

-

0.20 ± 0.03b A

0.17 ± 0.04b A

1.08 ± 0.02a A

0.99 ± 0.16A

1.83 ± 0.29 A

ND

7.84 ± 0.11b A

 

144

0.66 ± 0.22b A

0.51 ± 0.05c A

-

0.23 ± 0.05b A

0.26 ± 0.03c A

1.68 ± 0.35b A

1.28 ± 0.30A

2.30 ± 0.36 A

ND

6.61 ± 0.19a A

Metabolite concentrations are expressed in mM, bacterial counts are expressed in ufc mL−1 Columns for the same carbon source with different lower case letter superscripts indicate significant differences along time (p > 0.05). Different capital letters superscripts indicate significant differences among carbon sources at the same sampling point (p < 0.05). * Sum of acetic, propionic, lactic, succinic, formic and pyruvic acids. + Counts at 0 h were 7.02 ± 0.08 log ufc mL−1. WCS without carbon source. -, under the detection limit, ND Not determined

The production of fermentation end-products from the catabolism of carbohydrates by B. fragilis was notably higher in glucose than in EPS and also in medium with the different EPS than in the medium without carbohydrates added all along the incubation period considered in the study (p < 0.05) (Table 1). Glucose was depleted in the culture medium after 24 h (data not shown) and metabolite levels remained without noticeable variations until 144 h of incubation. In contrast, total metabolites produced in medium with both EPS increased continuously until the end of fermentation, reaching clearly higher levels at the end of the incubation period in the culture with EPS E44 than in EPS R1 (p < 0.05). We analysed more in depth the evolution pattern of the different organic acids and SCFA formed during incubation (Table 1). The acetic to propionic acids ratio displayed higher values in glucose than in both EPS (p < 0.05) whereas, conversely, the propionic to succinic as well as the acetic to lactic acid ratios showed a trend (p < 0.1) to display higher values in cultures with EPS than with glucose. Regarding levels of the different microbial metabolites in cultures with EPS, the acetic, propionic and succinic acids increased until 24 h, decreased from 24 to 48–72 h, and increased again until the end of incubation. On the opposite, the concentration of lactic acid reached the maximum value at 48 h and then experienced a continuous decrease until the end of incubation (p < 0.05). As a consequence, at 48 h the acetic to lactic acid ratio reached its minimum value whereas the acetic to propionic ratio attained its maximum in cultures with EPS E44.

Since the only carbon source available in our experimental conditions were either glucose or EPS, we examined the evolution of the EPS fractions over time, looking for detectable variations in the amount and/or physicochemical characteristics of the polymer peaks that could demonstrate their consumption. Peaks of EPS E44, purified from the cellular biomass of Bif. longum E44, were according to that previously reported [22] and consisted in two polymers, one of 5 × 106 Da (E44 P1) representing 18.8 % of the total mass, and a second one of 9 × 103 Da (E44 P2), representing 81.2 % (Additional file 2: Figure S2). We ruled out any change in the molar mass distribution of the EPS E44 fraction along incubation in uninoculated MM (data not shown). Interestingly, the incubation of EPS with B. fragilis in the MM resulted in a significant decrease in the amount of the higher molar mass peak (E44 P1) of E44 from 48 h to 144 h of incubation (p < 0.05) (Fig. 1a and b) and of the smaller molar mass peak (E44 P2) between 48 and 72 h of incubation, remaining stable from 72 to 144 h (p < 0.05) (Fig. 1a and b). Molar mass distribution of EPS R1 was also in accordance with that previously reported by us [24], and consisted of three peaks; one of 1 × 106 Da (R1 P1), another one of 2.35 × 104 Da (R2 P2) and a small one of 4 × 103 Da (R3 P3). This last peak overlapped in our analysis with an UV absorption peak and was then excluded from our study (Additional file 2: Figure S2). The total amount of the higher molar mass R1 polymer (R1 P1) did not show a decrease at the end of incubation, independently on the presence of B. fragilis (Fig. 1d). The amount of the medium size polymer (R1 P2) suffered an apparent depletion along incubation, which reached statistical significance at late incubation times (48, 72 and 144 h, p <0.05); however, the final amount of this polymer in the MM without B. fragilis was not significantly different (p > 0.05) from the values obtained in the culture with bacteria added (Fig. 1c and d) (statistical data not shown).
Fig. 1

Time course of the bifidobacterial EPS degradation by B. fragilis. Refractive index chromatogram for degradation of EPS E44 peaks along time (a). Evolution of the total amount of EPS E44 peaks along time (b). Refractive index chromatogram for degradation of EPS R1 peaks along time (c). Evolution of the total amount of the two biggest peaks of EPS R1 fraction along time (d). Significant reduction of the amount of EPS in the corresponding peak with respect to time 0 is indicated by asterisks (p < 0.05). Dashed red lines indicate the amount of polymer for each peak after 144 h of incubation in the absence of B. fragilis

Discussion

The use of bacterial EPS by Bacteroides thetaiotaomicron has been described before with HoPS produced by some lactic acid bacteria and Streptococcus spp. [6, 16, 25]. Although the use of HePS from bifidobacteria had not been definitely demonstrated yet, we have previously identified changes in the metabolism of B. fragilis in the presence of these polymers in an undefined medium [18]. Results from the current study demonstrated an effective growth of this specie in the presence of HePS. As compared to glucose, Bacteroides population levels attained with our EPS at early stages of growth were lower, but probably the slow utilization of these polymers and hence their availability as carbon source along incubation contributed to maintain the microbial levels at late states of growth, this phenomenon being more pronounced with EPS E44 than with EPS R1. Besides, a differential metabolic activity of B. fragilis in the presence of EPS as compared to glucose was evidenced. B. fragilis remained metabolically active in cultures with EPS for a longer period of time, with the highest activity corresponding to the cultures with the polymer E44. Variations obtained in metabolic profiles of Bacteroides cultures as depending on the carbon sources were similar to those indicated previously by us using an undefined medium [18]. Additionally, higher propionic to succinic acid ratios with complex carbon sources relative to glucose, similar to that found in the current study, have been previously reported [26].

In the present study we observed a clear shift in the metabolite production by B. fragilis during the time course of fermentation in the presence of EPS with respect to glucose, which was more pronounced with the polymer E44 than with R1. Coinciding with the depletion in the amount of EPS polymers from 48 h of incubation, a gradual increase in the concentrations of acetic, propionic and succinic acids and a decrease in the levels of lactic acid occurred until the end of incubation. It has been previously suggested that, in Bacteroides, the production of propionate through the succinate/propionate pathway could be a cell response to optimize cell energy production while keeping the intracellular redox balance [18, 19]. Although B. fragilis has the capacity to metabolize moderate amounts of lactic acid [27] as well as amino acids [28], our work was performed in a minimal medium, so that no amino acid sources were available and the scarce consumption of lactic acid that may occur does not explain the growth and metabolic activity of the bacterium in such conditions.

The results from SEC-MALS chromatography indicated that B. fragilis was able to use the EPS E44 produced by Bif. longum as a fermentable substrate. The chemical structure of EPS E44 has not been elucidated yet but it is known that EPS E44 contains glucose and galactose in its composition [22]. It is then possible that the saccharolytic enzymatic machinery of B. fragilis could include enzymes able to participate in the degradation of this complex substrate. On the other hand, changes in growth and metabolic patterns occurring at late stages of growth in EPS E44 could be related with the cessation of consumption of the smaller peak beyond 72 h of incubation, and hence with a scarcity of carbon source available from this time. Our results are not conclusive about the possible degradation of the EPS R1 fraction by B. fragilis. Even though there were no significant changes attributable to the activity of B. fragilis in the EPS peaks of high and medium molar mass, we could not rule out changes in the amount of the smallest polymer, not considered in our study because the overlapping with a protein peak. Variations in this small polymer may provide a possible explanation for the increased metabolic activity evidenced in cultures of B. fragilis until 72 h of incubation in the presence of the EPS R1 fraction as compared to the control in MM without carbon sources added. The EPS R1 fraction is formed by glucose, galactose and rhamnose [24] and only the chemical structure of the high molar mass peak has been determined to date, which is composed by 50 % rhamnose [29]. Although we know that the presence of both EPS stimulates the production of α-glucosidase by B. fragilis, the high molar mass polymer of the EPS R1 fraction lacks the α-linkages targeted by this enzymatic activity [29]. This together with the inability of B. fragilis to ferment rhamnose [28], could pose difficulties for the use as fermentable substrate of the EPS R1 by this microorganism.

The ability of B. fragilis to use bifidobacterial EPS may provide this microorganism with a long-term available complex carbon source, thus enhancing its survival and conferring it a selective advantage in environments where nutrients are scarce, such as the case of the human large intestine. Bacteroides plays an important role in the utilization of indigestible dietary compounds and complex polymers secreted by other microorganisms [6]. Some EPS and capsular polysaccharides are involved in adhesion to eukaryotic cells, biofilm formation and protection of several species against the gastrointestinal stressing factors [14]. In this way the ability of Bacteroides to degrade these polymers may confer this microorganism a role in the regulation of microbial relationships in the gut ecosystem. Fermentation of EPS in faecal cultures lead to an increase in propionic acid production [17], most likely due to the metabolic activity of members from the genus Bacteroides.

Conclusions

The present work is the first report demonstrating that B. fragilis is able to use some EPS produced by a bifidobacteria as substrate for growth, which resulted in a partial polymer consumption and the concomitant release of metabolic end products from its fermentation. By extrapolating these findings to the human gut, it may be hypothesized that the feeding relationship between microbial EPS and Bacteroides could have an impact in the SCFA production balance in the gut, which is ultimately related with the human health.

Abbreviations

EPS, Exopolysaccharide; GAMc, Gifu Anaerobic Medium with cysteine; HePS, Heteroexopolysaccharides; HoPS, Homopolysaccharides; MM, Minimal medium; SCFA, Short Chain Fatty Acids; SEC-MALLS, Size-Exclusion chromatography-Multiangle Laser Light Scattering

Declarations

Acknowledgments

David Ríos-Covián was the recipient of a predoctoral FPI fellowship granted by MINECO. We would like to thank Lidia Alaez for her excellent technical assistance.

Funding

This work was financed by projects AGL2010-16525 and AGL2013-43770-R from Plan Nacional/Plan Estatal de I + D + I (Spanish Ministry of Economy and Competitiveness, MINECO) and the Grant GRUPIN14-043 from “Plan Regional de Investigación del Principado de Asturias”. Both, national and regional grants received cofounding from European Union FEDER funds.

Availability of data and materials

All the data supporting these paper findings is contained within the article and in the supplementary files.

Authors’ contribution

DRC participated in the design of the experiment and carried out the bacterial cultures, data analysis and interpretation of results, and drafted the manuscript. IC carried out the HPLC analysis. JRA performed the GC analysis. PRM participated in the analysis and interpretation of MALLS data. MG participated in the study design and data interpretation. CGR participated in the study design and data interpretation. All authors revised and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent to publish

Not applicable.

Ethics and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Probiotics and Prebiotics Group, Department of Microbiology and Biochemistry of Dairy Products, Instituto de Productos Lácteos de Asturias, Consejo Superior de Investigaciones Científicas (IPLA-CSIC)
(2)
Scientific and Technical Facilities, Instituto de Productos Lácteos de Asturias, Consejo Superior de Investigaciones Científicas (IPLA-CSIC)

References

  1. Flint HJ, Duncan SH, Scott KP, Louis P. Links between diet, gut microbiota composition and gut metabolism. Proc Nutr Soc. 2015;74:13–22.View ArticlePubMedGoogle Scholar
  2. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1:6ra14.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Rigottier-Gois L, Bourhis AG, Gramet G, Rochet V, Dore J. Fluorescent hybridisation combined with flow cytometry and hybridisation of total RNA to analyse the composition of microbial communities in human faeces using 16S rRNA probes. FEMS Microbiol Ecol. 2003;43:237–45.View ArticlePubMedGoogle Scholar
  4. Lozupone CA, Hamady M, Cantarel BL, Coutinho PM, Henrissat B, Gordon JI, Knight R. The convergence of carbohydrate active gene repertoires in human gut microbes. Proc Natl Acad Sci U S A. 2008;105:15076–81.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Xu J, Mahowald MA, Ley RE, Lozupone CA, Hamady M, Martens EC, et al. Evolution of symbiotic bacteria in the distal human intestine. PLoS Biol. 2007;5:e156.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Sonnenburg ED, Zheng H, Joglekar P, Higginbottom SK, Firbank SJ, Bolam DN, Sonnenburg JL. Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell. 2010;141:1241–52.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20:593–621.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci U S A. 2009;106:5859–64.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Namavar F, Theunissen EB, Verweij-Van Vught AM, Peerbooms PG, Bal M, Hoitsma HF, MacLaren DM. Epidemiology of the Bacteroides fragilis group in the colonic flora in 10 patients with colonic cancer. J Med Microbiol. 1989;29:171–6.View ArticlePubMedGoogle Scholar
  10. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122:107–18.View ArticlePubMedGoogle Scholar
  11. Kuwahara T, Yamashita A, Hirakawa H, Nakayama H, Toh H, Okada N, Kuhara S, Hattori M, Hayashi T, Ohnishi Y. Genomic analysis of Bacteroides fragilis reveals extensive DNA inversions regulating cell surface adaptation. Proc Natl Acad Sci U S A. 2004;101:14919–24.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Ruas-Madiedo P, Moreno JA, Salazar N, Delgado S, Mayo B, Margolles A, de los Reyes-Gavilan CG. Screening of exopolysaccharide-producing Lactobacillus and Bifidobacterium strains isolated from the human intestinal microbiota. Appl Environ Microbiol. 2007;73:4385–8.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Ruas-Madiedo P, Gueimonde M, Arigoni F, de los Reyes-Gavilan CG, Margolles A. Bile affects the synthesis of exopolysaccharides by Bifidobacterium animalis. Appl Environ Microbiol. 2009;75:1204–7.View ArticlePubMedGoogle Scholar
  14. Hidalgo-Cantabrana C, Sánchez B, Milani C, Ventura M, Margolles A, Ruas-Madiedo P. Genomic overview and biological functions of exopolysaccharide biosynthesis in Bifidobacterium spp. Appl Environ Microbiol. 2014;80:9–18.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Salazar N, Gueimonde M, Hernandez-Barranco AM, Ruas-Madiedo P, de los Reyes-Gavilan CG. Exopolysaccharides produced by intestinal Bifidobacterium strains act as fermentable substrates for human intestinal bacteria. Appl Environ Microbiol. 2008;74:4737–45.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Grosu-Tudor SS, Zamfir M, Meulen RVD, Falony G, Vuyst LC. Prebiotic potential of some exopolysaccharides produced by lactic acid bacteria. Rom Biotechnol Lett. 2013;18:8666–76.Google Scholar
  17. Salazar N, Ruas-Madiedo P, Kolida S, Collins M, Rastall R, Gibson G, de los Reyes-Gavilan CG. Exopolysaccharides produced by Bifidobacterium longum IPLA E44 and Bifidobacterium animalis subsp. lactis IPLA R1 modify the composition and metabolic activity of human faecal microbiota in pH-controlled batch cultures. Int J Food Microbiol. 2009;135:260–7.View ArticlePubMedGoogle Scholar
  18. Rios-Covian D, Sanchez B, Salazar N, Martinez N, Redruello B, Gueimonde M, de los Reyes-Gavilan CG. Different metabolic features of Bacteroides fragilis growing in the presence of glucose and exopolysaccharides of bifidobacteria. Front Microbiol. 2015;6:825.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Sperry JF, Appleman MD, Wilkins TD. Requirement of heme for growth of Bacteroides fragilis. Appl Environ Microbiol. 1977;34:386–90.PubMedPubMed CentralGoogle Scholar
  20. Ruas-Madiedo P, Gueimonde M, Margolles A, de los Reyes-Gavilan CG, Salminen S. Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. J Food Prot. 2006;69:2011–5.PubMedGoogle Scholar
  21. Delgado S, Ruas-Madiedo P, Suarez A, Mayo B. Interindividual differences in microbial counts and biochemical-associated variables in the feces of healthy Spanish adults. Dig Dis Sci. 2006;51:737–43.View ArticlePubMedGoogle Scholar
  22. Koropatkin NM, Smith TJ. SusG: A unique cell-membrane-associated α-amylase from a prominent human gut symbiont targets complex starch molecules. Structure. 2010;18:200–15. doi: http://dx.doi.org/10.1016/j.str.2009.12.010.View ArticlePubMedGoogle Scholar
  23. Salazar N, Prieto A, Leal JA, Mayo B, Bada-Gancedo JC, de los Reyes-Gavilan CG, Ruas-Madiedo P. Production of exopolysaccharides by Lactobacillus and Bifidobacterium strains of human origin, and metabolic activity of the producing bacteria in milk. J Dairy Sci. 2009;92:4158–68.View ArticlePubMedGoogle Scholar
  24. Ruas-Madiedo P, Medrano M, Salazar N, de los Reyes-Gavilan CG, Perez PF, Abraham AG. Exopolysaccharides produced by Lactobacillus and Bifidobacterium strains abrogate in vitro the cytotoxic effect of bacterial toxins on eukaryotic cells. J Appl Microbiol. 2010;109:2079–86.View ArticlePubMedGoogle Scholar
  25. van Bueren AL, Saraf A, Martens EC, Dijkhuizena L. Differential metabolism of exopolysaccharides from probiotic lactobacilli by the human gut symbiont Bacteroides thetaiotaomicron. Appl Environ Microbiol. 2015;81:3973–83.View ArticleGoogle Scholar
  26. Adamberg S, Tomson K, Vija H, Puurand M, Kabanova N, Visnapuu T, Jõgi E, Alamäe T, Adamberg K. Degradation of fructans and production of propionic acid by Bacteroides thetaiotaomicron are enhanced by shortage of amino acids. Front Nutr. 2014;1:21.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Rios-Covian D, Arboleya S, Hernandez-Barranco AM, Alvarez-Buylla JR, Ruas-Madiedo P, Gueimonde M, de los Reyes-Gavilan CG. Interactions between Bifidobacterium and Bacteroides species in cofermentations are affected by carbon sources, including exopolysaccharides produced by bifidobacteria. Appl Environ Microbiol. 2013;79:7518–24.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Wexler HM. The genus Bacteroides. In: The Prokaryotes: Other Major Lineages of Bacteria and The Archaea. 2013. p. 459–84.Google Scholar
  29. Leivers S, Hidalgo-Cantabrana C, Robinson G, Margolles A, Ruas-Madiedo P, Laws AP. Structure of the high molecular weight exopolysaccharide produced by Bifidobacterium animalis subsp. lactis IPLA-R1 and sequence analysis of its putative eps cluster. Carbohydr Res. 2011;346:2710–7.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016